The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.

In today's edition, David and Austin discuss Human Genome Sciences' recent rejection of partner GlaxoSmithKline's buyout offer. Big pharma has been on the hunt recently, snapping up assets and restocking pipelines to mitigate the damage from the patent cliff. David and Austin catch viewers up on why HGS is an attractive asset for Glaxo and why HGS management declined a seemingly generous gift to shareholders who are down significantly over the last year.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

Austin Smith has no positions in the stocks mentioned above. David Williamson owns shares of Dendreon. The Motley Fool owns shares of Dendreon and GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.